Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

New Coalition Draws Attention to Plight of Those with Rare Diseases

Monroe Township, NJ, December 12, 2013 ― Andrew Kitchenman reports on NJ Spotlight that New Jersey pharmaceutical companies, healthcare providers and patient advocates are working together — in a newly-formed group called NJ Rare — to solve the vexing challenge of finding treatments for diseases that affect relatively few people and therefore are the focus of less research.

People with rare diseases face a wide range of challenges, including having few in-network doctors who specialize in treating their conditions; waiting for medications approved to treat their conditions; expenses for both treatments and existing drugs, and even waiting years to even receive a diagnosis. )

Julie Raskin has been active in the effort to launch NJ Rare, which is a project of the nonprofit National Organization for Rare Disorders. Speaking yesterday at a health policy forum focused on rare diseases, she said the the group should expand its reach beyond patient advocacy groups to include pharmaceutical companies, healthcare providers and insurers.

NJ Rare is advocating for increased attention to rare diseases among health policymakers.

“We need some sort of hub where we can all work together,” said Raskin, whose son Ben was born with a congenital hyperinsulinism, a rare disorder that leads to severe and prolonged low blood-sugar levels. Her son’s condition led her to become executive director of Congenital Hyperinsulinism International, which advocates for patients with the disorder.

Dr. Swati Sathe, director of inpatient neurology at St. Joseph’s Regional Medical Center in Paterson, proposed a series of steps to encourage treatment of rare diseases, including establishing more centers of excellence focused on single disorders and, when that’s not practical, to address a group of disorders that affect the same systems of the body.

Raskin noted that while there are many rare diseases — roughly 7,000 diseases affect fewer than 200,000 Americans — the patients share certain experiences, including shortages of specialists familiar with their ailment and trying to find successful treatments.

Taking part in a panel discussion at the forum, which was hosted by the pharmaceutical trade association the HealthCare Institute of New Jersey (HINJ) at the Forsgate Country Club in Monroe Township in Middlesex County, Raskin cited some potential benefits of the 2010 Affordable Care Act for patients with rare diseases, including the law’s prohibition on discriminating against people with pre-existing medical conditions.

Other panelists noted that most health plans available through the new health insurance marketplace in New Jersey have limited provider networks, which could make it more difficult to find providers who specialize in a specific disease – for example, the specialist might be out-of-network and even located in another state.

The cost of treatments poses another challenge.  For example, patients can find it difficult to get their insurance to cover medications that doctors use to treat rare diseases but which haven’t been approved by the Food and Drug Administration for that specific use.

In addition, Raskin noted that while the insurance marketplace provides subsidies to buy coverage for families with incomes up to $94,200, a family of four at the New Jersey average income of roughly $99,000 could struggle to pay the combination of insurance premiums — which could be more than $2,000 per month for a family plan that includes a wider network of providers — and out-of-pocket expenses, which are capped at $12,700 per year for a family.

Dr. Swati Sathe, director of inpatient neurology at St. Joseph’s Regional Medical Center in Paterson, said it’s a challenge for patients with rare disorders to even get a diagnosis. She said young doctors are less likely than older doctors to order tests to determine whether a patient has a rare disease.

That’s because there’s been a change in how doctors are trained, with an increased focus on diagnosing illnesses can be treated with existing medication, while many rare diseases cannot be addressed with available treatments, Dr. Sathe said.

Dr. Tanya Pagan Raggio-Ashley, an official with the regional office of the U.S. Department of Health and Human Services, highlighted the potential benefits of the ACA in combating rare diseases, including making healthcare more accessible through Medicaid expansion.

The keynote speaker at the event was John Crowley, chairman and CEO of Amicus Therapeutics, a biopharmaceutical company focused on rare genetic diseases.

Crowley has two children with Pompe disease and helped lead the effort that successfully developed treatments for the disorder. While he said the work on Pompe’s disease is an example of the successes that can occur through research on rare diseases, it was an incomplete success since the treatment isn’t a cure.

For Kitchenman’s full story, click here.